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Alterations of the genital mucosal barrier may influence the
number of viruses transmitted from a human immunodefi-
ciency virus–infected source host to the newly infected
individual. We used heteroduplex tracking assay and single-
genome sequencing to investigate the effect of a tenofovir-
based microbicide gel on the transmission bottleneck in
women who seroconverted during the CAPRISA 004 micro-
bicide trial. Seventy-seven percent (17 of 22; 95% confi-
dence interval [CI], 56%–90%) of women in the tenofovir
gel arm were infected with a single virus compared
with 92% (13 of 14; 95% CI, 67%–>99%) in the placebo arm
(P = .37). Tenofovir gel had no discernable impact on the
transmission bottleneck.
It is well established that there is a severe genetic bottleneck
associated with human immunodeficiency virus (HIV) trans-
mission, resulting in low genetic diversity in early infection.
Recently, larger studies that sequenced single HIV genomes
from mainly heterosexual cohorts were able to more accurately
quantitate this bottleneck [1–4]. It is estimated that approxi-
mately 80% (141 of 175) of sexually transmitted HIV infec-
tions are the result of only a single variant crossing the
mucosal barrier to establish clinical infection. However, HIV
and simian immunodeficiency virus studies have shown that
the virus transmission bottleneck is affected by both the dose
and the route of infection [4–7]. In macaques, a lower-dose
inoculum resulted in a reduced number of transmitted vari-
ants [6]. Although in both macaques and humans injection
drug use (IDU) resulted in an increased frequency of multiple-
variant infections [5, 7], a separate study from Russia found
that IDU did not relax the genetic bottleneck [8]. This conflict
in findings about IDU could be due to differences in cohort
characteristics, including risk behavious. Men who have sex
with men are also at higher risk of infection than heterosexu-
als [5] and were found to be twice as likely to acquire multi-
ple-variant HIV infections, possibly due to anatomical and
histological differences between the 2 modes of transmission
[4]. Similarly, inflammatory genital infections have also been
shown to be associated with both increased risk of transmis-
sion and multivariant infection [2]. Together these studies
suggest that breaching or bypassing the mucosal barrier can
mitigate the viral transmission bottleneck and that characteriz-
ing the diversity following transmission can provide a surro-
gate marker of increased transmission risk.
Microbicides for women aim to reinforce the vaginal epithe-
lial barrier against infection, although some microbicides, such
as nonoxyl-9, compromise the mucosal barrier and increase
the risk of transmission [9]. The recent pivotal CAPRISA 004
microbicide trial showed that women in urban and rural
KwaZulu-Natal, South Africa, who used 1% tenofovir-based
gel had a significantly lower incidence of HIV acquisition (5.6
per 100 women-years) than women on the placebo arm (9.1
per 100 women-years Africa) [10], with an overall 39% protec-
tive effect. These results demonstrate the utility of having
tenofovir at the site of transmission to inhibit the early rounds
of viral replication [10]. We studied intrapatient genetic diver-
sity of HIV infection in the CAPRISA 004 trial participants
with breakthrough infections to determine whether the use of
the 1% tenofovir gel affected the genetic bottleneck.
METHODS
Samples were provided from participants who seroconverted
while participating in the CAPRISA004 trial [10]. Date of in-
fection was defined as the midpoint between the last HIV-
negative test and the first HIV-positive test or as 14 days prior
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Figure 1. Envelope sequence analysis. (A) Neighbour-joining tree of envelope sequences for all participants analysed by SGA. Shaded branches
indicate multiple variant infections. (B-C) Typical V1/V2 and V4/V5-HTA results respectively for study participants labelled according to the last 3 digits
of the participant identification number. The number of viral variants are estimated by counting the number of heteroduplexes for each probe set
(shown below each gel). (D) Highlighter plot illustrating nucleotide mismatches within sequences compared to a consensus sequence for participant
314 who displayed discordant results between HTA and SGA analyses. Horizontal lines represent HIV envelope sequences, while the vertical ticks
indicate the nucleotide mismatches or sequence gaps. Black bars indicate the position of the V1/V2 (∼330 – 760 bp) (HXB2: 6555-6981) and V4/V5
(∼1120 – 1500 bp) (HXB2: 7341-7715) probe domains analysed in the HTA. (E) Comparison of the incidence of multiple variant infections between
individuals using the tenofovir-based microbicide trial and individuals not receiving treatment in the CAPRISA 002 acute infection cohort [1]












in the event of polymerase chain reaction (PCR)–positive,
antibody-negative result. In CAPRISA 004, 98 study partici-
pants became infected with HIV (tenofovir gel, n = 38;
placebo gel, n = 60). Two blinded panels of 43 and 7 samples
were provided, of 7 seven were excluded because participants
had been infected for >12 weeks, making it difficult to differ-
entiate between single and multiple variant infections due to
viral diversification [11]. A further 7 were not amplifiable, 5 of
which had low viral load copy number.
To differentiate between single- and multiple-variant HIV
transmission, we first screened for heterogeneity in 2 regions,
V1/V2 and V4/V5, using heteroduplex tracking assay (HTA)
because these variable regions of env are most likely to harbor
the highest sequence diversity. Each amplicon was annealed to
2 separate probes to further enhance the chance of detecting
sequence differences. Samples were classified as single-variant
infection if there was a dominant band for all 4 comparisons,
with the presence of a second band in 1 region accepted if it
was faint and suggestive of recent diversification from a single
founder. All samples classified as single-variant infections
contained ≥30 amplifiable copies, which is sufficient to repro-
ducibly quantify a 10% minority population [12]. Samples
were classified as potential multiple-variant infections if >1
dominant band was visualized in any region. Multiple bands
on a gel may be due to either multiple-variant transmission or
viral evolution from a single founder virus infection. To differ-
entiate these 2 scenarios, we used single genome amplification
(SGA) and sequencing [11].
Human immunodeficiency virus type 1 RNA was extracted
using the MagNA Pure RNA isolation kit (Roche Diagnostics).
Samples with viral loads ≤5000 copies/mL were concentrated by
centrifugation. For the HTA, the V1/V2 (HXB2: 6555–6981)
and V4/V5 (HXB2: 7341–7715) regions were PCR amplified as
described [13]. Amplicons were assayed using 2 sets of subtype
C–radiolabelled probes to each of the V1/V2 and V4/V5 env
domains [13]. For HIV-1 env SGA analysis, participant comple-
mentary DNAs were diluted to a single copy and amplified as
described [1, 3]. Sequences were excluded if they contained >1
double peak in the sequence chromatogram or deletions >100
nucleotides. A single double peak in the sequence chromato-
gram was permitted only if it was not located in the same posi-
tion as other double peaks from the same participant.
Pairwise DNA distances and neighbor-joining phylogenetic
trees were computed using MEGA 4.1. [14]. Sequence differ-
ences were visualised using Highlighter nucleotide transition
and transversion plots (http://www.hiv.lanl.gov). Time of di-
vergence from the most recent common ancestor (tMRCA)
was estimated using Bayesian Evolutionary Analysis Sampling
Trees version 1.4.7 [15], as described previously [1, 3].
All P values are 2-sided and calculated using Fisher’s exact
test, and all confidence intervals (CIs) are 95% and calculated
using GraphPad Prism version 5.00.
This study was approved by both the University of Cape
TownResearch Ethics Committee (025/2004) and theUniversity
of KwaZulu-Natal Biomedical Research Ethics Committee.
RESULTS
To determine the genetic complexity of HIV following trans-
mission in women exposed to tenofovir vs placebo, we
screened 29 of the 36 samples by HTA. This method is sensi-
tive to detecting small sequence differences between variants,
which are visualized as altered migration patterns of heterodu-
plexes in a gel (Figure 1). Eighteen participants were classified
as being infected with a single-variant infection based on the
presence of a single dominant band in both env variable
domains assayed; in 6 of these participants, there was evidence
of diversification from a single founder detected as faint addi-
tional bands in 1 region (Table 1; Figure 1B and 1C). Eleven
individuals were identified with high-diversity infection based
on multiple bands.
Twenty samples were sequenced using the single genome
amplification approach: in addition to the 11 samples identi-
fied as putative multiple-variant infections by HTA, a further
7 were sequenced because there was no HTA analysis avail-
able, and 2 samples were sequenced as controls (participant-
292, HTA detected no diversity; and participant-310, HTA
detected diversity in 1 variable region). In total, 363 sequences
were generated (median of 20 per participant) spanning the
first approximately 1950 nucleotides of gp160, including the
entire gp120. All 20 participants were infected with HIV-1
subtype C (Figure 1A).
Classification of single-variant transmission was based on
low intraparticipant sequence diversity with no or limited
structure in the phylogenetic tree and genetic differences
within the expected range for the duration of infection [3].
Based on these criteria, 11 individuals were classified as
having single-variant infections, of which 5 had been identi-
fied as having putative multiple-variant transmissions using
HTA. Heteroduplex tracking assay is very sensitive to se-
quence changes, and the accuracy of defining the number of
transmitted viruses is greatest when sampling is close to the
date of transmission. The samples with multiple bands were
acquired at >6 weeks postinfection and had evidence of
immune pressure, including sequence gaps in the V1/V2 env
domains, which accounted for the diversification (Table 1;
Figure 1D). The mean of the maximum sequence diversity in
the single-variant infections was 0.2% and ranged 0%–0.3%.
The classification as single-variant transmission was supported
by the estimated time to tMRCA, which was within the range
of the duration of infection (Table 1). Combining the HTA
and sequencing results, 30 participants were identified as
being infected with a single variant.












Five participants were classified as infected with multiple var-
iants based on high pairwise distance of the sequences, struc-
ture in the phylogenetic tree, and tMRCA predating the
estimated date of infection (Table 1). In 1 of the 5 participants
(participant-299), we were not able to generate sufficient ampli-
cons to estimate tMRCA; however, the phylogenetic analysis
and maximum genetic distance of 1.3% were sufficient to confi-
dently classify this individual as having a multiple-variant





















304 M 42 94 900 1 Single
372 M 22 107 000 1 Single
323 M 24 22 000 1 Single Yes
367 M 24 3 360 000 1 Single Yes
310 M 30 305 000 1a 0.10 9 (1–19) Single Yes
362 M 30 44 200 1 Single
355 M 32 19 700 1 Single Yes
370 M 34 28 800 1 Single Yes
320 M 35 37 500 1a Single
375 M 38 192 000 1a Single
363 M 38 97 500 >1 0.30 93 (41–153) Single
334 M 44 21 200 1 Single Yes
352 M 51 107 000 1 Single
314 M 57 166 000 >1 0.40 111 (53–176) Single
343 M 63 130 000 >1 0.40 75 (42–112) Single
358 M 67 717 1 Single
305 M 78 45 600 >1 0.50 120 (74–173) Single
325 M 22 127 000 >1 NA NA Multiple Yes
360 M 25 80 600 >1 1.60 883 (291–1794) Multiple Yes
318 M 31 22 300 >1 1.00 573 (242–1083) Multiple
283 M 45 6650 >1 1.30 870 (398–1443) Multiple
348 M 58 305 000 >1 2.60 1615 (901–2559) Multiple Yes
Placebo
302 P 21 1 980 000 NA 0.30 49 (27–73) Single
303 P 21 506 000 NA 0.50 12 (1–32) Single
290 P 21 84 500 NA 0.70 23 (4–55) Single Yes
315 P 21 108 000 NA 0.50 147 (87–215) Single
327 P 21 91 600 1a Single
351 P 22 104 000 1 Single
312 P 23 1850 1a Single Yes
307 P 28 155 000 NA 0.30 55 (25–90) Single Yes
289 P 28 142 000 NA 0.50 38 (4–84) Single Yes
297 P 38 8000 >1 0.20 58 (16–115) Single
292 P 39 458 000 1 0.20 9 (1–25) Single
317 P 49 351 000 NA 0.40 81 (45–122) Single
308 P 62 37 100 1a Single
299 P 16 5080 >1 1.20 Multiple Yes
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HTA, heteroduplex tracking assay; MRCA, most recent common ancestor; NA, not
available; PID, participant identification number; STI, sexually transmitted infection.
a Single dominant band in both variable env regions (V1/V2, V3/V4), with a faint band in 1 region indicative of recent diversification.
b MRCA calculated using Bayesian evolutionary analysis by sampling trees.
c STI screen (Karim et al, 2010): syphilis, Trichomonas vaginalis, Neisseria gonorrhoea, Chlamydia trachomatis, Mycoplasma genitalium, bacterial vaginosis, and
herpes simplex virus type 2.












infection (Table 1). A sixth participant (participant-325) was
classified as infected with multiple variants because, although
we were unable to sequence the virus, there were clear multiple
dominant bands on HTA gels in both genomic regions, a
banding pattern that exceeded that expected for the short dura-
tion of infection (approximately 3 weeks). Of these 6 partici-
pants, 5 were from the tenofovir gel arm, and 1 was from the
placebo arm.
In summary, to determine if the use of the 1% tenofovir gel
affected the mucosal barrier, thereby altering the genetic bot-
tleneck associated with transmission, we defined multiplicity
of infection in 36 participants: 22 were from the tenofovir gel
arm and 14 were from the placebo arm. We found that the
frequency of single-variant infection was not significantly dif-
ferent between the tenofovir gel and placebo arms (P = .37),
with a single virus responsible for 17 (77%; 95% CI, 56%–
90%) infections in the tenofovir arm and 13 (93%; 95% CI,
67%–>99%) infections in the placebo arm. In a previous study
of 69 men and women from Malawi and South Africa, we
found 78% of infections involved single-variant transmission.
Of these, 26 were women from the CAPRISA 002 cohort,
which recruited from the same population and geographical
region. The percentage of single-virus transmission in the te-
nofovir arm was identical to that of gel-unexposed participants
reported for the CAPRISA 002 cohort (20 of 26; 77%) [1]
(Figure 1E).
DISCUSSION
No alteration in the transmission bottleneck in the break-
through HIV infections in the tenofovir gel arm of the
CAPRISA 004 microbicide trial was detected. The single-virus
transmission rates were not significantly different between the
tenofovir gel and placebo gel: 77% of the women from the te-
nofovir gel arm (17 of 22) and 93% from the placebo gel arm
(13 of 14) (P = .37) had HIV infections that were a result of a
single variant. Further, the single-virus transmission rate in
the tenofovir gel arm was similar to that from a previous
study [1] in a similar group of women not exposed to the mi-
crobicide or placebo gel.
These results provide further insights into the dynamics of
transmission in the CAPRISA 004 tenofovir trial [10]. Past
studies in African heterosexual cohorts found significantly in-
creased (50%) incidence of multiple-variant infections in indi-
viduals with compromised vaginal mucosal barriers [2]. In the
CAPRISA004 trial, genital samples were tested for sexually
transmitted infections (STIs) at first diagnosis of HIV-1 infec-
tion (Table 1) [10]. In the subset of participants included in
the current study, no difference (P = 1.00) in the incidence of
STIs was observed between the 2 study arms, and the presence
of STIs, albeit in a limited sample size, did not appear
to impact the incidence of multiple-variant transmission
(P = .21).
The results presented here from the CAPRISA 004 tenofovir
gel trial show no significant increase in the incidence of
multiple-variant infections in the tenofovir gel– or placebo-
using arm of the trial and an identical frequency in the inci-
dence of multiple-variant infections to individuals recruited
from similar communities who did not use the gel (Figure 1E).
Although we included all but 1 of the amplifiable samples
from the tenofovir gel users, it should be noted that this
limited sample size would only have detected a large effect of
the microbicide on the transmission bottleneck. In conclusion,
the protective effect of tenofovir gel [12], together with the
maintenance of the multiplicity of infection between different
groups (1% for the tenofovir gel group, the placebo gel group,
and the non-gel users from a similar community), suggests
that the microbicide did not compromise the vaginal mucosa
barrier.
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